SABS | tickerfilter.com

Fundamental analysis

11%

Profitability 0%

Dept financing 10%

Liquidity 75%

Performance 7%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.77%

1 Month

-26.28%

3 Months

-70.05%

6 Months

-57.41%

1 Year

-74.22%

2 Year

-72.02%

Key data

Stock price

$1.15

P/E Ratio

0.00

DAY RANGE

$1.05 - $1.17

EPS

-$0.79

52 WEEK RANGE

$1.00 - $5.01

52 WEEK CHANGE

-$74.73

MARKET CAP

24.919 M

YIELD

N/A

SHARES OUTSTANDING

9.229 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

-0.16

PUBLIC FLOAT

AVERAGE 10 VOLUME

$33,526

AVERAGE 30 VOLUME

$38,945

Company detail

CEO: Eddie J. Sullivan
Region: US
Website: sabbiotherapeutics.com
Employees: 140
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

SAB Biotherapeutics, Inc. engages in the development of immunotherapies based on human antibodies. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

SABS - SAB Biotherapeutics, Inc.